- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07560293
3D-EIT for Diagnosis and Monitoring of Pulmonary Embolism (TIDE-PE)
Prospective Validation of Three-Dimensional Electrical Impedance Tomography for the Diagnosis, Risk Stratification, and Longitudinal Monitoring of Pulmonary Embolism
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
Pulmonary embolism (PE) is a major cause of morbidity and mortality. Computed tomography pulmonary angiography (CTPA) is the current reference standard for PE diagnosis, but it is limited by radiation exposure, contrast administration, and poor suitability for bedside or repeated dynamic assessment. Three-dimensional electrical impedance tomography (3D-EIT) is a non-invasive, radiation-free imaging technique that enables bedside evaluation of regional lung ventilation and perfusion.
The objective of this study is to validate the clinical utility of 3D-EIT for the diagnosis, risk stratification, and longitudinal monitoring of PE. The study will focus on EIT-derived ventilation-perfusion parameters, including the Matching Index (MI), Dead Space Index (DI), and Shunt Index (SI).
This is a prospective, single-center, observational case-control study conducted at Beijing Tsinghua Changgung Hospital. Two cohorts will be enrolled:
- A control cohort without PE or VTE, recruited from patients scheduled for saphenous vein radiofrequency ablation for varicose veins who meet predefined screening criteria.
- A PE cohort including patients with a first episode of PE confirmed by CTPA. Participants in the control cohort will undergo one 3D-EIT examination to establish reference ranges for MI, DI, and SI. Participants in the PE cohort will undergo 3D-EIT within 24 hours after diagnostic CTPA. Repeated EIT examinations will be performed after thrombolytic therapy when applicable, at hospital discharge, and at 1-month follow-up to evaluate dynamic changes over time.
The primary objective is to assess the diagnostic performance of MI and DI for identifying PE using CTPA as the reference standard. Secondary objectives include evaluating the association of EIT-derived indices with PE severity, CTPA-based obstruction burden, risk stratification category, and temporal changes following treatment.
Statistical analyses will include estimation of reference ranges in the control cohort, receiver operating characteristic (ROC) analysis for diagnostic performance, correlation analyses between EIT and CTPA-derived parameters, and longitudinal analyses of repeated EIT measurements in the PE cohort.
Undersøgelsestype
Tilmelding (Anslået)
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Age 18 years or older
- Body mass index (BMI) less than 50 kg/m²
- Able to provide written informed consent
- first episode of pulmonary embolism confirmed by CT pulmonary angiography (CTPA), with or without CT venography (CTV)
Exclusion Criteria:
- Previous diagnosis of pulmonary embolism
- Pregnancy
- Thoracic deformity or chest wall abnormality preventing proper placement of the EIT electrode belt
- Contraindications to EIT use, including implantable cardioverter-defibrillator, pacemaker, implanted pumps, or chest wounds limiting electrode placement
- Concurrent participation in another interventional clinical study Hemodynamic instability requiring emergency intervention that precludes completion of the EIT examination (PE cohort only)
- Any other condition judged by the investigator to make the participant unsuitable for study participation
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Diagnostic Accuracy of EIT-derived Dead Space Index (DI) for Pulmonary Embolism
Tidsramme: Baseline (within 24 hours after CTPA for the PE cohort and at enrollment for the control cohort)
|
Sensitivity, specificity, and area under the receiver operating characteristic curve (AUC) of the Dead Space Index (DI) measured by 3D-EIT for diagnosing pulmonary embolism, using CT pulmonary angiography (CTPA) as the reference standard.
|
Baseline (within 24 hours after CTPA for the PE cohort and at enrollment for the control cohort)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Diagnostic Accuracy of EIT-derived Matching Index (MI) for Pulmonary Embolism
Tidsramme: Baseline (within 24 hours after CTPA for the PE cohort and at enrollment for the control cohort)
|
Sensitivity, specificity, and area under the receiver operating characteristic curve (AUC) of the Matching Index (MI) measured by 3D-EIT for diagnosing pulmonary embolism, using CT pulmonary angiography (CTPA) as the reference standard.
|
Baseline (within 24 hours after CTPA for the PE cohort and at enrollment for the control cohort)
|
Samarbejdspartnere og efterforskere
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 3D-EIT for PE
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Venøs tromboembolisme (VTE)
-
Feeltect LimitedParkview HealthIkke rekrutterer endnuVenous bensår (VLUS)Forenede Stater
-
Alexion Pharmaceuticals, Inc.Portola Pharmaceuticals, LLC (a wholly owned subsidiary of Alexion Pharmaceuticals)AfsluttetVTE-profylakseForenede Stater, Det Forenede Kongerige, Den Russiske Føderation, Ukraine
-
Janssen Research & Development, LLCAfsluttetVTE-profylakse med antikoagulering efter total knæudskiftningsoperationBelgien, Italien, Malaysia, Letland, Spanien, Kalkun, Bulgarien, Forenede Stater, Litauen, Den Russiske Føderation, Ukraine, Japan, Argentina, Brasilien, Canada, Polen
-
Thomas Jefferson UniversityRekrutteringAmning | Efter fødslen | Indsamling af modermælk | Rivaroxaban | VTE-profylakse | VTE (venøs tromboembolisme)Forenede Stater
-
Chinese Academy of Medical Sciences, Fuwai HospitalUkendt
-
StimLabsIkke rekrutterer endnuBensår | Venøse bensår | Bensår Venøs | Venøst ben | Venous bensår (VLUS)
-
Infanta Leonor University HospitalFundación para la Investigación e Innovación Biomédica del Hospital Universitario...RekrutteringVenøs tromboembolisme (VTE) | Okkult kræftSpanien
-
McMaster UniversityCanadian Venous Thromboembolism Clinical Trials and Outcomes Research... og andre samarbejdspartnereIkke rekrutterer endnuVenøs tromboembolisme (VTE) | Hoftefrakturkirurgi | Kardiovaskulær forebyggelseCanada, Italien
-
Regeneron PharmaceuticalsRekrutteringVenøs tromboembolisme (VTE)Forenede Stater, Japan, Litauen, Ungarn, Letland, Polen, Bulgarien, Rumænien
-
University Hospital, BrestRekrutteringVenøs tromboembolisme (VTE)Frankrig